Compare DELL & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DELL | SNY |
|---|---|---|
| Founded | 1984 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.7B | 107.3B |
| IPO Year | 2013 | N/A |
| Metric | DELL | SNY |
|---|---|---|
| Price | $179.47 | $48.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 5 |
| Target Price | ★ $172.07 | $58.00 |
| AVG Volume (30 Days) | ★ 7.5M | 2.9M |
| Earning Date | 05-28-2026 | 04-23-2026 |
| Dividend Yield | 1.14% | ★ 3.36% |
| EPS Growth | ★ 36.05 | N/A |
| EPS | ★ 8.68 | N/A |
| Revenue | ★ $113,538,000,000.00 | N/A |
| Revenue This Year | $26.15 | $3.86 |
| Revenue Next Year | $8.65 | $5.64 |
| P/E Ratio | $21.26 | ★ $6.14 |
| Revenue Growth | ★ 18.80 | N/A |
| 52 Week Low | $80.74 | $43.32 |
| 52 Week High | $191.37 | $55.73 |
| Indicator | DELL | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 58.66 | 62.53 |
| Support Level | $116.60 | $46.88 |
| Resistance Level | $186.39 | $48.88 |
| Average True Range (ATR) | 8.17 | 0.74 |
| MACD | -0.37 | 0.14 |
| Stochastic Oscillator | 66.11 | 95.20 |
Dell Technologies is a broad information technology vendor, primarily supplying hardware to enterprises. It focuses on premium and commercial personal computers, as well as enterprise on-premises data center hardware. It holds top-three shares in its core markets of personal computers, peripheral displays, mainstream servers, and external storage. Dell has a robust ecosystem of component and assembly partners and also relies heavily on channel partners to fulfill its sales.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.